Metabolic pathways involved in 2-methoxyestradiol synthesis and their role in preeclampsia

Reproductive Sciences

Volumn 20, Issue 9, 2013, Pages 1020-1029

  Perez Sepulveda, Alejandra ^a   España Perrot, Pedro P ^a   Norwitz, Errol R ^b   Illanes, Sebastián E ^a  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 methoxyestradiol (2 ME); aromatase; hypoxia; methionine homocysteine metabolism; preeclampsia

Indexed keywords

2 METHOXYESTRADIOL; ANDROSTENEDIONE; AROMATASE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; ESTRADIOL; HOMOCYSTEINE; METHIONINE; SULFOTRANSFERASE 1A1; TESTOSTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; BIOAVAILABILITY; BREAST METASTASIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CYTOTROPHOBLAST; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME METABOLISM; ENZYME SYNTHESIS; FETUS GROWTH; FIRST TRIMESTER PREGNANCY; GENE EXPRESSION; HUMAN; HYPOXIA; MATERNAL HYPERTENSION; MENSTRUAL CYCLE; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLACENTA CIRCULATION; PREECLAMPSIA; PREGNANCY DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN METHYLATION; REGULATORY MECHANISM; SOLID TUMOR; SYNCYTIOTROPHOBLAST; SYSTEMATIC REVIEW (TOPIC); TROPHOBLAST;

2-METHOXYESTRADIOL (2-ME); AROMATASE; HYPOXIA; METHIONINE-HOMOCYSTEINE METABOLISM; PREECLAMPSIA;

ANIMALS; AROMATASE; BIOLOGICAL MARKERS; CATECHOL O-METHYLTRANSFERASE; ESTRADIOL; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84882445860     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719113477483     Document Type: Article

References (88)

1. Hypertension in pregnancy. Number 219 - January 1996 (replaces no. 91, February 1986). Committee on technical bulletins of the American college of obstetricians and gynecologists. Int J Gynaecol Obstet. 1996 ; 53 (2). 175-183
2. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007 ; 335 (7627). 974
3. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J. 2008 ; 156 (5). 918-930
4. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000 ; 183 (1). S1 - S22
5. Knofler M, Pollheimer J. IFPA award in placentology lecture: molecular regulation of human trophoblast invasion. Placenta. 2012 ; 33 (suppl). S55 - S62
6. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol. 1996 ; 175 (5). 1365-1370
7. Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006 ; 11 (5). 309-316
8. Redman CW. Current topic: pre-eclampsia and the placenta. Placenta. 1991 ; 12 (4). 301-308
9. Pijnenborg R, Vercruysse L, Brosens I. Deep placentation. Best Pract Res Clin Obstet Gynaecol. 2011 ; 25 (3). 273-285
10. Hunkapiller NM, Fisher SJ. Chapter 12. Placental remodeling of the uterine vasculature. Methods Enzymol. 2008 ; 445: 281-302
11. Whitley GS, Cartwright JE. Trophoblast-mediated spiral artery remodelling: a role for apoptosis. J Anat. 2009 ; 215 (1). 21-26
12. Lyall F. Mechanisms regulating cytotrophoblast invasion in normal pregnancy and pre-eclampsia. Aust N Z J Obstet Gynaecol. 2006 ; 46 (4). 266-273
13. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu. 1972 ; 1: 177-191
14. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol. 1986 ; 93 (10). 1049-1059
15. Rodesch F, Simon P, Donner C, Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol. 1992 ; 80 (2). 283-285
16. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science. 1997 ; 277 (5332). 1669-1672
17. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev. 1998 ; 8 (5). 588-594
18. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995 ; 270 (3). 1230-1237
19. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999 ; 399 (6733). 271-275
20. Caniggia I, Mostachfi H, Winter J, et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest. 2000 ; 105 (5). 577-587
21. Librach CL, Werb Z, Fitzgerald ML, et al. 92-kD type IV collagenase mediates invasion of human cytotrophoblasts. J Cell Biol. 1991 ; 113 (2). 437-449
22. Lee SB, Wong AP, Kanasaki K, et al. Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol. 2010 ; 176 (2). 710-720
23. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999 ; 180 (2 pt 1). 499-506
24. Kanasaki K, Palmsten K, Sugimoto H, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature. 2008 ; 453 (7198). 1117-1121
25. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ. Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 2002 ; 62 (13). 3691-3697
26. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res. 1999 ; 5 (3). 493-499
27. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature. 1994 ; 368 (6468). 237-239
28. Zacharia LC, Jackson EK, Gillespie DG, Dubey RK. Increased 2-methoxyestradiol production in human coronary versus aortic vascular cells. Hypertension. 2001 ; 37 (2 part 2). 658-662
29. Shang W, Konidari I. Schomberg DW. 2-Methoxyestradiol, an endogenous estradiol metabolite, differentially inhibits granulosa and endothelial cell mitosis: a potential follicular antiangiogenic regulator. Biol Reprod. 2001 ; 65 (2). 622-627
30. Becker CM, Rohwer N, Funakoshi T, et al. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol. 2008 ; 172 (2). 534-544
31. Lakhani NJ, Sarkar MA, Venitz J. Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy. 2003 ; 23 (2). 165-172
32. Pasquier E, Sinnappan S, Munoz MA, Kavallaris M. ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 ; 9 (5). 1408-1418
33. Hou Y, Meyers CY, Akomeah M. A short, economical synthesis of 2-methoxyestradiol, an anticancer agent in clinical trials. J Org Chem. 2009 ; 74 (16). 6362-6364
34. Berg D, Sonsalla R, Kuss E. Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh). 1983 ; 103 (2). 282-288
35. Barnes CM, McElrath TF, Folkman J, Hansen AR. Correlation of 2-methoxyestradiol levels in cord blood and complications of prematurity. Pediatr Res. 2010 ; 67 (5). 545-550
36. Pérez-Sepúlveda A, Torres MJ, Valenzuela FJ, et al. Low 2-methoxyestradiol levels at the first trimester of pregnancy are associated with the development of pre-eclampsia. Prenat Diagn. 2012 ; 32 (11). 1-6
37. Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999 ; 51 (4). 593-628
38. Palmer K, Saglam B, Whitehead C, Stock O, Lappas M, Tong S. Severe early-onset preeclampsia is not associated with a change in placental catechol O-methyltransferase (COMT) expression. Am J Pathol. 2011 ; 178 (6). 2484-2488
39. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996 ; 6 (3). 243-250
40. Syvanen AC, Tilgmann C, Rinne J, Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics. 1997 ; 7 (1). 65-71
41. Sata F, Yamada H, Suzuki K, et al. Functional maternal catechol-O-methyltransferase polymorphism and fetal growth restriction. Pharmacogenet Genomics. 2006 ; 16 (11). 775-781
42. Stanley JL, Andersson IJ, Poudel R, et al. Sildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout mouse model. Hypertension. 2012 ; 59 (5). 1021-1028
43. Barnea ER, MacLusky NJ, DeCherney AH, Naftolin F. Catechol-o-methyl transferase activity in the human term placenta. Am J Perinatol. 1988 ; 5 (2). 121-127
44. Roten LT, Fenstad MH, Forsmo S, et al. A low COMT activity haplotype is associated with recurrent preeclampsia in a Norwegian population cohort (HUNT2). Mol Hum Reprod. 2011 ; 17 (7). 439-446
45. Lim JH, Kim SY, Kim do J, et al. Genetic polymorphism of catechol-O-methyltransferase and cytochrome P450c17alpha in preeclampsia. Pharmacogenet Genomics. 2010 ; 20 (10). 605-610
46. Liang S, Liu X, Fan P, et al. Association between Val158Met functional polymorphism in the COMT gene and risk of preeclampsia in a Chinese population. Arch Med Res. 2012 ; 43 (2). 154-158
47. Hill LD, York TP, Kusanovic JP, et al. Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia. PLoS One. 2011 ; 6 (1). e16681
48. Ananth CV, Elsasser DA, Kinzler WL, et al. Polymorphisms in methionine synthase reductase and betaine-homocysteine S-methyltransferase genes: risk of placental abruption. Mol Genet Metab. 2007 ; 91 (1). 104-110
49. Sharma P, Senthilkumar RD, Brahmachari V, et al. Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids Health Dis. 2006 ; 5: 1
50. Walker MC, Smith GN, Perkins SL, Keely EJ, Garner PR. Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol. 1999 ; 180 (3 pt 1). 660-664
51. Cikot RJ, Steegers-Theunissen RP, Thomas CM, de Boo TM, Merkus HM, Steegers EA. Longitudinal vitamin and homocysteine levels in normal pregnancy. Br J Nutr. 2001 ; 85 (1). 49-58
52. Murphy MM, Scott JM, McPartlin JM, Fernandez-Ballart JD. The pregnancy-related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution, or a decrease in albumin in a longitudinal study. Am J Clin Nutr. 2002 ; 76 (3). 614-619
53. Steegers-Theunissen RP, Wathen NC, Eskes TK, van Raaij-Selten B, Chard T. Maternal and fetal levels of methionine and homocysteine in early human pregnancy. Br J Obstet Gynaecol. 1997 ; 104 (1). 20-24
54. Powers RW, Evans RW, Majors AK, et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol. 1998 ; 179 (6 pt 1). 1605-1611
55. Wang J, Trudinger BJ, Duarte N, Wilcken DE, Wang XL. Elevated circulating homocyst(e)ine levels in placental vascular disease and associated pre-eclampsia. BJOG. 2000 ; 107 (7). 935-938
56. D'Anna R, Baviera G, Corrado F, Ientile R, Granese D, Stella NC. Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction. Acta Obstet Gynecol Scand. 2004 ; 83 (2). 155-158
57. Makedos G, Papanicolaou A, Hitoglou A, et al. Homocysteine, folic acid and B12 serum levels in pregnancy complicated with preeclampsia. Arch Gynecol Obstet. 2007 ; 275 (2). 121-124
58. Lopez-Quesada E, Vilaseca MA, Lailla JM. Plasma total homocysteine in uncomplicated pregnancy and in preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2003 ; 108 (1). 45-49
59. Cotter AM, Molloy AM, Scott JM, Daly SF. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of nonsevere preeclampsia. Am J Obstet Gynecol. 2003 ; 189 (2). 391-394
60. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006 ; 132 (2). 171-196
61. Valenzuela FJ, Perez-Sepulveda A, Torres MJ, Correa P, Repetto GM, Illanes SE.. Pathogenesis of preeclampsia: the genetic component. J Pregnancy. 2012 ; 2012: 632732
62. Shenoy V, Kanasaki K, Kalluri R. Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends Endocrinol Metab. 2010 ; 21 (9). 529-536
63. Troisi R, Potischman N, Roberts JM, et al. Correlation of serum hormone concentrations in maternal and umbilical cord samples. Cancer Epidemiol Biomarkers Prev. 2003 ; 12 (5). 452-456
64. Ghorashi V, Sheikhvatan M. The relationship between serum concentration of free testosterone and pre-eclampsia. Endokrynol Pol. 2008 ; 59 (5). 390-392
65. Carlsen SM, Romundstad P, Jacobsen G. Early second-trimester maternal hyperandrogenemia and subsequent preeclampsia: a prospective study. Acta Obstet Gynecol Scand. 2005 ; 84 (2). 117-121
66. Sowers MR, Wilson AL, Kardia SR, Chu J, Ferrell R. Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife. Am J Med. 2006 ; 119 (9 suppl 1). S23 - S30
67. Somner J, McLellan S, Cheung J, et al. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2004 ; 89 (1). 344-351
68. Kidokoro K, Ino K, Hirose K, et al. Association between CYP19A1 polymorphisms and sex hormones in postmenopausal Japanese women. J Hum Genet. 2009 ; 54 (2). 78-85
69. Hertig A, Liere P, Chabbert-Buffet N, et al. Steroid profiling in preeclamptic women: evidence for aromatase deficiency. Am J Obstet Gynecol. 2010 ; 203 (5). e471-477
70. Czajka-Oraniec I, Simpson ER. Aromatase research and its clinical significance. Endokrynol Pol. 2010 ; 61 (1). 126-134
71. Simpson ER, Clyne C, Rubin G, et al. Aromatase - a brief overview. Annu Rev Physiol. 2002 ; 64: 93-127
72. Conley A, Hinshelwood M. Mammalian aromatases. Reproduction. 2001 ; 121 (5). 685-695
73. Hong Y, Li H, Yuan YC, Chen S. Molecular characterization of aromatase. Ann N Y Acad Sci. 2009 ; 1155: 112-120
74. Zhou H, Fu G, Yu H, Peng C. Transforming growth factor-beta inhibits aromatase gene transcription in human trophoblast cells via the Smad2 signaling pathway. Reprod Biol Endocrinol. 2009 ; 7: 146
75. Williams MA, Woelk GB, King IB, Jenkins L, Mahomed K. Plasma carotenoids, retinol, tocopherols, and lipoproteins in preeclamptic and normotensive pregnant Zimbabwean women. Am J Hypertens. 2003 ; 16 (8). 665-672
76. Zhu SJ, Li Y, Li H, et al. Retinoic acids promote the action of aromatase and 17beta-hydroxysteroid dehydrogenase type 1 on the biosynthesis of 17beta-estradiol in placental cells. J Endocrinol. 2002 ; 172 (1). 31-43
77. Milczarek R, Sokolowska E, Hallmann A, Klimek J. The NADPH- and iron-dependent lipid peroxidation in human placental microsomes. Mol Cell Biochem. 2007 ; 295 (1-2). 105-111
78. Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev. 2005 ; 57 (2). 217-252
79. Jiang B, Kamat A, Mendelson CR. Hypoxia prevents induction of aromatase expression in human trophoblast cells in culture: potential inhibitory role of the hypoxia-inducible transcription factor Mash-2 (mammalian achaete-scute homologous protein-2). Mol Endocrinol. 2000 ; 14 (10). 1661-1673
80. Caniggia I, Winter JL. Adriana and Luisa Castellucci Award lecture 2001. Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and pre-eclamptic pregnancies - a review. Placenta. 2002 ; 23 (suppl A). S47 - S57
81. Tao MH, Cai Q, Zhang ZF, et al. Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev. 2007 ; 16 (5). 943-949
82. Ma CX, Adjei AA, Salavaggione OE, et al. Human aromatase: gene resequencing and functional genomics. Cancer Res. 2005 ; 65 (23). 11071-11082
83. Nagar S, Walther S, Blanchard RL. Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol Pharmacol. 2006 ; 69 (6). 2084-2092
84. Nowell S, Falany CN. Pharmacogenetics of human cytosolic sulfotransferases. Oncogene. 2006 ; 25 (11). 1673-1678
85. Adjei AA, Thomae BA, Prondzinski JL, Eckloff BW, Wieben ED, Weinshilboum RM. Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. Br J Pharmacol. 2003 ; 139 (8). 1373-1382
86. Aksoy IA, Wood TC, Weinshilboum R. Human liver estrogen sulfotransferase: identification by cDNA cloning and expression. Biochem Biophys Res Commun. 1994 ; 200 (3). 1621-1629
87. Song WC, Moore R, McLachlan JA, Negishi M. Molecular characterization of a testis-specific estrogen sulfotransferase and aberrant liver expression in obese and diabetogenic C57BL/KsJ-db/db mice. Endocrinology. 1995 ; 136 (6). 2477-2484
88. Falany JL, Azziz R, Falany CN. Identification and characterization of cytosolic sulfotransferases in normal human endometrium. Chem Biol Interact. 1998 ; 109 (1-3). 329-339